Dascena Inc., a machine-learning diagnostic algorithm company, closed on a $50 million Series B financing round led by Frazier Healthcare Partners. The Oakland, California-based company targets early disease intervention, such as acute decompensation (heart failure), sepsis and acute kidney injury, to improve patient care outcomes. In addition to Frazier, the funding round also included Longitude Capital, existing investor Euclidean Capital and an undisclosed investor, according to a company press release. Ritankar Das, founder and CEO of Dascena, said in a written statement that more than 250,000 patients die of sepsis annually. Dascena's flagship sepsis algorithm, InSight, has helped reduce the number of deaths by 58 percent and decrease the length of hospital stay by 21 percent, in patients with sepsis, according to the company.